RYTM

Rhythm Pharmaceuticals
RYTM

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$3.64B
EV
$3.59B
Shares Outstanding
67.52M
Beta
2.37

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$82.08
P/E 2025E
-
P/Revenue 2025E
20.77x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Rhythm Pharmaceuticals, Inc.

gainify
RYTM

Rhythm Pharmaceuticals, Inc.

RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), ...

Sector

Healthcare

Industry

Biotechnology

CEO

Meeker, David

Employees

283

IPO Date

2017-10-09

Headquarters

222 Berkeley Street, 12th Floor, Boston, Massachusetts, 02116, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on Instagram
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.